The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Trinity Bio has an asset utilization ratio of 25.83 percent. This suggests that the company is making $0.26 for each dollar of assets. An increasing asset utilization means that Trinity Bio ADR is more efficient with each dollar of assets it utilizes for everyday operations.
What is the right price you would pay to acquire a share of Trinity Biotech? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the
future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our
stock advisor page.
What is happening with Trinity Biotech plc this year
Annual and quarterly reports issued by Trinity Biotech plc are formal
financial statements that are published yearly and quarterly and sent to Trinity stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the
Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Trinity Biotech often view their annual report as an effective marketing tool to disseminate their perspective on company
future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
Trinity Biotech Gross Profit
Trinity Biotech Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Trinity Biotech previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Trinity Biotech Gross Profit growth over the last 10 years. Please check Trinity Biotech's
gross profit and other
fundamental indicators for more details.
Is Trinity a risky opportunity?
Let's check the volatility. Trinity is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Trinity (NASDAQ:TRIB) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. taking in a share of a Trinity Bio stock makes you a part-owner of that company.
Trinity Bio ADR Current Consensus
Here is the current trade recommendation based on an ongoing consensus estimate among financial analysis covering Trinity Bio ADR. The Trinity consensus assessment is calculated by taking the average estimates from all of the analysts covering Trinity Bio
| Strong Buy | 0 | 0.0 |
| Buy | 1 | 33.33 |
| Hold | 2 | 66.67 |
| Sell | 0 | 0.0 |
| Strong Sell | 0 | 0.0 |
Trinity Bio is likely to close below $1.36 next week
Trinity Bio current potential upside builds up over 7.48. Trinity Bio ADR shows above-average downside volatility for the selected time horizon. We advise investors to inspect Trinity Bio ADR further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Trinity Bio future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Trinity Bio's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Trinity Bio's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Trinity Bio Implied Volatility
Trinity Bio's implied volatility exposes the market's sentiment of Trinity Bio ADR stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Trinity Bio's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Trinity Bio stock will not fluctuate a lot when Trinity Bio's options are near their expiration.
Our Final Perspective on Trinity Bio
Whereas some other entities under the diagnostics & research industry are still a bit expensive, Trinity Bio may offer a potential longer-term growth to investors. With a relatively neutral outlook on the current economy, it is better to hold off any trading of Trinity as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Trinity Bio.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Gabriel Shpitalnik is a Member of Macroaxis Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Trinity Biotech plc. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
